corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Company profile
Ticker
CRVS
Exchange
Website
CEO
Richard Miller
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Corvus Biopharmaceuticals, Ltd. • Corvus Hong Kong Limited ...
CRVS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
19 Mar 24
8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
19 Mar 24
8-K
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
23 Jan 24
8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Other Events
6 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
EFFECT
Notice of effectiveness
9 May 23
Transcripts
CRVS
Earnings call transcript
2023 Q4
19 Mar 24
CRVS
Earnings call transcript
2023 Q3
7 Nov 23
CRVS
Earnings call transcript
2023 Q2
8 Aug 23
CRVS
Earnings call transcript
2023 Q1
8 May 23
CRVS
Earnings call transcript
2022 Q4
27 Mar 23
CRVS
Earnings call transcript
2022 Q3
3 Nov 22
CRVS
Earnings call transcript
2022 Q2
9 Aug 22
CRVS
Earnings call transcript
2021 Q4
11 Mar 22
CRVS
Earnings call transcript
2020 Q2
2 Aug 20
CRVS
Earnings call transcript
2020 Q1
2 May 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.11 mm | 20.11 mm | 20.11 mm | 20.11 mm | 20.11 mm | 20.11 mm |
Cash burn (monthly) | (no burn) | 373.58 k | 1.85 mm | 1.95 mm | 1.81 mm | 2.19 mm |
Cash used (since last report) | n/a | 2.57 mm | 12.77 mm | 13.44 mm | 12.48 mm | 15.11 mm |
Cash remaining | n/a | 17.53 mm | 7.34 mm | 6.66 mm | 7.63 mm | 5.00 mm |
Runway (months of cash) | n/a | 46.9 | 4.0 | 3.4 | 4.2 | 2.3 |
Institutional ownership, Q3 2023
49.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 55 |
Opened positions | 8 |
Closed positions | 11 |
Increased positions | 15 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 27.19 bn |
Total shares | 24.19 mm |
Total puts | 70.50 k |
Total calls | 48.10 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 6.94 mm | $10.14 bn |
Adams Street Partners | 3.28 mm | $4.78 bn |
Samlyn Capital | 2.41 mm | $3.51 bn |
Integrated Core Strategies | 1.90 mm | $0.00 |
Richard A Miller MD | 1.49 mm | $0.00 |
Biotechnology Value Fund L P | 1.37 mm | $3.30 mm |
BVF | 1.37 mm | $2.00 bn |
Vanguard | 1.35 mm | $1.97 bn |
BLK Blackrock | 521.25 k | $761.03 mm |
Renaissance Technologies | 421.74 k | $616.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Jeffrey Arcara | Stock Option Common Stock | Grant | Acquire A | No | No | 2.3 | 400,000 | 920.00 k | 400,000 |
6 Dec 23 | Gould Terry P | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 15,000 | 24.60 k | 15,000 |
6 Dec 23 | Thompson Peter A. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 15,000 | 24.60 k | 15,000 |
6 Dec 23 | Ian T Clark | Stock Option Common Stock | Grant | Acquire A | No | No | 1.64 | 15,000 | 24.60 k | 15,000 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Apr 24
Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
9 Apr 24
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma
1 Apr 24
Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
27 Mar 24
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
20 Mar 24
Press releases
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
9 Apr 24
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
13 Mar 24
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
12 Feb 24